PLYX

Polaryx Therapeutics Inc

1.99

Sep 03 • 3:59 PM ET -0.05 (-2.45%)

1.99

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Sep 01, 8:35 AMPolaryx Therapeutics appoints Dr. Will Charlton as Chief Medical Officer ahead of SOTERIA Phase 2 trial in Q4 2026

Peers: CAMP CNTN CNTX RNA TLSA UNCY KPTI MGNX IFRX TENX

| Held by: VTI VXF

Scroll to Statements

Index	-
Market Cap	99.20M
Enterprise Value	87.66M
Income	-6.85M
Sales	0.00M
Book/sh	0.22
Cash/sh	0.23
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	11
IPO	Feb 02, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	9.07
P/C	8.60
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	13.53
Current Ratio	13.53
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-0.14
EPS next Y	-0.29
EPS next Q	-0.04
EPS this Y	2.50%
EPS next Y	-47.44%
EPS next 5Y	-21.27%
EPS past 3/5Y	-54.22% -
Sales past 3/5Y	- -
EPS Y/Y TTM	9.65%
Sales Y/Y TTM	-
EPS Q/Q	-34.27%
Sales Q/Q	-
Earnings	Jun 03
EPS/Sales Surpr.	-150.00% -

Insider Own	91.95%
Insider Trans	0.19%
Inst Own	4.40%
Inst Trans	-1.13%
ROA	-89.21%
ROE	-96.56%
ROIC	-62.61%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-6.59%
SMA50	-11.25%
SMA200	-51.42%
Trades

Shs Outstand	49.85M
Shs Float	4.01M
Short Float	6.21%
Short Ratio	2.20
Short Interest	0.25M
52W High	48.91 -95.93%
52W Low	1.85 7.57%
Volatility	6.40% 9.86%
ATR (14)	0.19
RSI (14)	43.51
Beta	-
Rel Volume	0.19
Avg Volume	113.24K
Volume	21,056

Perf Week	-5.69%
Perf Month	-11.16%
Perf Quarter	-21.34%
Perf Half Y	-24.05%
Perf YTD	-95.58%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	7.50
Prev Close	2.04
Price	1.99
Change %	-2.45%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-26	Initiated	Raymond James	Strong Buy	$6
Jul-09-26	Initiated	H.C. Wainwright	Buy	$7
Feb-27-26	Initiated	Maxim Group	Buy	$10

Sep-01-26 08:30AM	Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer (GlobeNewswire)
Aug-25-26 08:30AM	Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial (GlobeNewswire) +6.42%
May-28-26 08:30AM	Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial (GlobeNewswire) +21.51%
May-14-26 09:15AM	Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards (GlobeNewswire)
Apr-23-26 08:30AM	Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference (GlobeNewswire)
08:30AM	Loading…
Apr-21-26 08:30AM	Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial (GlobeNewswire) -7.54%
Apr-15-26 09:15AM	Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care (GlobeNewswire)
Apr-01-26 08:30AM	Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-26 08:30AM	Polaryx Therapeutics Receives FDA Fast Track Designation for PLX-200 for Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) (GlobeNewswire)
Mar-12-26 08:30AM	Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events (GlobeNewswire) -19.27%
Feb-27-26 08:30AM	Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders (GlobeNewswire)
Feb-17-26 10:26AM	Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans (Benzinga) +64.32%
08:30AM	Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial (GlobeNewswire)
Feb-10-26 08:30AM	Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium (GlobeNewswire) -24.11%
Feb-05-26 08:30AM	Polaryx Therapeutics Welcomes New Members of the Board of Directors (GlobeNewswire) -28.89%
08:40AM	Loading…
Feb-04-26 08:40AM	Polaryx to present late-breaker data related to Soteria ahead of trial (TipRanks)
Feb-03-26 08:30AM	Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium as Company Prepares for SOTERIA Trial Launch (GlobeNewswire) -37.29%
Feb-02-26 08:30AM	Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol "PLYX" (GlobeNewswire)

Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. Its pipeline of products includes PLX-100, PLX-200, and PLX-300. The company was founded by Hahn-Jun Lee on August 22, 2014 and is headquartered in Paramus, NJ.

L.L.M.Mr. Alex Yang J.D.

CFO & DirectorMr. G. Michael Landis CPA

Chief Investment OfficerMr. Andrew John O

Ph.D.Dr. Shrijay Vijayan M.B.A.

Ph.D.Mr. Wuxin Zhu P.M.P.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Yang Alex Keun Mo	Chief Executive Officer	May 27 '26	Buy	4.07	88,453	360,004	24,233,249	May 28 08:00 PM
Landis G. Michael	Chief Financial Officer	Feb 18 '26	Buy	2.79	2,867	7,991	228,225	Feb 20 04:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PLYX

Polaryx Therapeutics Inc

Upgrade your Finviz experience